Individualisation of basal insulin therapy of type 2 diabetes: evidence from large randomized controlled trials
Initiation of insulin therapy with basal insulin analogues has become the standard of care for type 2 diabetes mellitus (T2DM). Timely administration of insulin allows not only to slow down the progression of type 2 diabetes, but also to reduce the frequency and severity of complications associated...
Saved in:
| Main Authors: | S. V. Nedogoda, I. N. Barykina, A. S. Salasyuk, V. O. Lutova, E. A. Popova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2023-01-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/12774 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
by: Ivan Ivanovich Dedov, et al.
Published: (2014-12-01) -
The use of long-acting insulin degludec in adult patients with type 2 diabetes mellitus in real clinical practice in Russia
by: G. R. Galstyan
Published: (2023-02-01) -
Modern basal insulins: an ongoing story or the start of a new era?
by: Ivan Ivanovich Dedov
Published: (2015-12-01) -
The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
by: M. V. Shestakova, et al.
Published: (2021-07-01) -
Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study
by: Elena Valer'evna Biryukova, et al.
Published: (2012-09-01)